Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft by ¹⁸F-FLT MicroPET/CT Imaging

Figure 4

Immunohistochemical and histologic analysis of tumor sections about CD31, Ki67, and H&E on days 0, 1, 3, 7, and 13 after therapy. Top line showed H&E staining in the Sunitinib group. CD31 staining in the Sunitinib group revealed effective antiangiogenic activity from day 1 to day 7 ((a) control, (b) Sunitinib, and 40×10, (e)). Ki67 showed a remarkable decrease after the initiation of treatment, which was the most pronounced one on day 3 compared with that for the control tumors ((c) control, (d) Sunitinib, and 40×10, (f)). T/M of ¹⁸F-FLT uptakes of tumor in the treatment group were correlated well with the quantitative data of MVD (g) and Ki67 SI (h). ^∗𝑃<0.05 and ^∗∗𝑃<0.01, within the Sunitinib group, compared to day 0. ^■𝑃<0.05 and ^■■𝑃<0.01, between the Sunitinib group and the control group.

(a)  

(b)

(c)

(d)

(e)

(f)

(g)

(h)